Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival
2 意见
• 07/10/23
0
0
嵌入
The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论